Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

[Targeted radionuclide therapy - where should we go ?].

Kinuya S.

Gan To Kagaku Ryoho. 2013 Feb;40(2):133-8. Review. Japanese.

PMID:
23411948
2.

Patient dosimetry in radionuclide therapy: the whys and the wherefores.

Thierens HM, Monsieurs MA, Bacher K.

Nucl Med Commun. 2005 Jul;26(7):593-9. Review.

PMID:
15942479
3.

Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours.

Nijsen JF, van het Schip AD, Hennink WE, Rook DW, van Rijk PP, de Klerk JM.

Curr Med Chem. 2002 Jan;9(1):73-82. Review.

PMID:
11860349
4.

A new era for radiolabeled antibodies in cancer?

DeNardo SJ, Kroger LA, DeNardo GL.

Curr Opin Immunol. 1999 Oct;11(5):563-9. Review.

PMID:
10508716
5.

Endoradiotherapy in cancer treatment--basic concepts and future trends.

Zoller F, Eisenhut M, Haberkorn U, Mier W.

Eur J Pharmacol. 2009 Dec 25;625(1-3):55-62. doi: 10.1016/j.ejphar.2009.05.035. Epub 2009 Oct 15. Review.

PMID:
19836381
6.

Targeted alpha therapy with 213Bi.

Morgenstern A, Bruchertseifer F, Apostolidis C.

Curr Radiopharm. 2011 Oct;4(4):295-305. Review.

PMID:
22202152
7.

Anti-cancer radiopharmaceuticals.

Hoefnagel CA.

Anticancer Drugs. 1991 Apr;2(2):107-32. Review.

PMID:
1958857
8.

Radiotargeting agents for cancer therapy.

Kassis AI.

Expert Opin Drug Deliv. 2005 Nov;2(6):981-91. Review.

PMID:
16296803
10.

Therapy with radiopharmaceuticals.

Carlsson J, Forssell-Aronsson E, Glimelius B, Mattsson S; Swedish Cancer Society Investigation Group.

Acta Oncol. 2002;41(7-8):623-8. Review.

PMID:
14651205
11.

Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.

Bauman G, Charette M, Reid R, Sathya J.

Radiother Oncol. 2005 Jun;75(3):258-70. Review.

PMID:
16299924
12.

State of the art of therapy in nuclear medicine.

Becker W.

Rev Esp Med Nucl. 2000 Oct;19(6):437-51. Review. No abstract available.

13.

The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.

Robbins RJ, Schlumberger MJ.

J Nucl Med. 2005 Jan;46 Suppl 1:28S-37S. Review.

14.

[Development of bifunctional radiopharmaceuticals for targeted imaging and therapy].

Mukai T.

Yakugaku Zasshi. 2007 Dec;127(12):1937-45. Review. Japanese.

15.

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.

D'Huyvetter M, Xavier C, Caveliers V, Lahoutte T, Muyldermans S, Devoogdt N.

Expert Opin Drug Deliv. 2014 Dec;11(12):1939-54. doi: 10.1517/17425247.2014.941803. Epub 2014 Jul 18. Review.

16.

Radiation and gene therapy: rays of hope for the new millennium?

Boyd M, Spenning HS, Mairs RJ.

Curr Gene Ther. 2003 Aug;3(4):319-39. Review.

PMID:
12871020
17.

Dosimetry in Peptide radionuclide receptor therapy: a review.

Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G.

J Nucl Med. 2006 Sep;47(9):1467-75. Review.

18.

Applications of gene transfer to targeted radiotherapy.

Mairs RJ, Cunningham SH, Boyd M, Carlin S.

Curr Pharm Des. 2000 Sep;6(14):1419-32. Review.

PMID:
10903401
19.

Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique.

Roos DE, Smith JG.

Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):493-5. Review.

PMID:
10348276
20.

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.

Druce MR, Lewington V, Grossman AB.

Neuroendocrinology. 2010;91(1):1-15. doi: 10.1159/000227808. Epub 2009 Jul 7. Review.

PMID:
19590162

Supplemental Content

Support Center